TY - JOUR
T1 - Contrast-enhanced ultrasound liver imaging reporting and data system for diagnosing hepatocellular carcinoma
T2 - A meta-analysis
AU - Shin, Jaeseung
AU - Lee, Sunyoung
AU - Bae, Heejin
AU - Chung, Yong Eun
AU - Choi, Jin‑Young
AU - Huh, Yong Min
AU - Park, Mi‑Suk
N1 - Publisher Copyright:
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
PY - 2020/10/1
Y1 - 2020/10/1
N2 - Background & aims: Contrast-enhanced ultrasound (CEUS) Liver Imaging Reporting and Data System (LI-RADS) is a comprehensive system for standardizing CEUS at high risk for hepatocellular carcinoma (HCC). We performed a meta-analysis to determine the diagnostic performance of the CEUS LR-5 for HCC and the pooled proportions of HCCs in each CEUS LI-RADS category. Methods: We searched multiple databases for studies reporting the diagnostic accuracy of the CEUS LI-RADS. Random-effects model was used to determine summary estimates of the diagnostic performance of CEUS LR-5 and the pooled proportions of HCCs in each CEUS LI-RADS category. Risk of bias and concerns regarding applicability were evaluated with the Quality Assessment of Diagnostic Accuracy Studies-2 tool. Results: Eleven studies were included in the final analysis, which consisted of 5535 observations with 3983 HCCs. The pooled per-observation sensitivity and specificity of the CEUS LR-5 for diagnosing HCC were 69% (95% confidence interval [CI], 64%–73%) and 92% (95% CI, 83%–96%) respectively. The pooled proportions of HCCs were 0% (95% CI, 0-0%) for LR-1, 1% (95% CI, 0%–4%) for CEUS LR-2, 26% (95% CI, 14%–39%) for CEUS LR-3, 77% (95% CI, 68%–86%) for CEUS LR-4, 97% (95% CI, 95%–98%) for CEUS LR-5, 57% (95% CI, 44%–69%) for CEUS LR-M and 100% (95% CI, 93%–100%) for CEUS LR-5V or TIV. Conclusions: The CEUS LR-5 category showed moderate sensitivity and high specificity for diagnosing HCC. The proportion of HCCs was higher in the higher CEUS LI-RADS categories.
AB - Background & aims: Contrast-enhanced ultrasound (CEUS) Liver Imaging Reporting and Data System (LI-RADS) is a comprehensive system for standardizing CEUS at high risk for hepatocellular carcinoma (HCC). We performed a meta-analysis to determine the diagnostic performance of the CEUS LR-5 for HCC and the pooled proportions of HCCs in each CEUS LI-RADS category. Methods: We searched multiple databases for studies reporting the diagnostic accuracy of the CEUS LI-RADS. Random-effects model was used to determine summary estimates of the diagnostic performance of CEUS LR-5 and the pooled proportions of HCCs in each CEUS LI-RADS category. Risk of bias and concerns regarding applicability were evaluated with the Quality Assessment of Diagnostic Accuracy Studies-2 tool. Results: Eleven studies were included in the final analysis, which consisted of 5535 observations with 3983 HCCs. The pooled per-observation sensitivity and specificity of the CEUS LR-5 for diagnosing HCC were 69% (95% confidence interval [CI], 64%–73%) and 92% (95% CI, 83%–96%) respectively. The pooled proportions of HCCs were 0% (95% CI, 0-0%) for LR-1, 1% (95% CI, 0%–4%) for CEUS LR-2, 26% (95% CI, 14%–39%) for CEUS LR-3, 77% (95% CI, 68%–86%) for CEUS LR-4, 97% (95% CI, 95%–98%) for CEUS LR-5, 57% (95% CI, 44%–69%) for CEUS LR-M and 100% (95% CI, 93%–100%) for CEUS LR-5V or TIV. Conclusions: The CEUS LR-5 category showed moderate sensitivity and high specificity for diagnosing HCC. The proportion of HCCs was higher in the higher CEUS LI-RADS categories.
UR - http://www.scopus.com/inward/record.url?scp=85089103443&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089103443&partnerID=8YFLogxK
U2 - 10.1111/liv.14617
DO - 10.1111/liv.14617
M3 - Article
C2 - 32722894
AN - SCOPUS:85089103443
SN - 1478-3223
VL - 40
SP - 2345
EP - 2352
JO - Liver International
JF - Liver International
IS - 10
ER -